<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112137</url>
  </required_header>
  <id_info>
    <org_study_id>NLN5031</org_study_id>
    <nct_id>NCT01112137</nct_id>
  </id_info>
  <brief_title>Effects of Clopidogrel on Blood Pressure</brief_title>
  <official_title>Phase IV Study of the Effects of Clopidogrel on Soluble CD40 Ligand, Endothelial Function and Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Context: Soluble CD40 ligand (sCD40L) released from activated platelets induces inflammatory&#xD;
      transformation of the vascular endothelium and is an independent predictor of cardiovascular&#xD;
      events. Arterial hypertension is associated with platelet activation, increased sCD40L levels&#xD;
      and endothelial dysfunction suggesting that inhibition of platelet-derived sCD40L release may&#xD;
      improve endothelial function and lower blood pressure (BP).&#xD;
&#xD;
      Objective: To determine the effects of clopidogrel on sCD40L, endothelial function and BP.&#xD;
&#xD;
      Design: Randomized, controlled, investigator-blinded, parallel-group, 2-phase trial in&#xD;
      patients with coronary artery disease and essential arterial hypertension and those without&#xD;
      hypertension.&#xD;
&#xD;
      Intervention: Participants receive a single 600-mg clopidogrel loading dose (phase I)&#xD;
      followed by a daily 75-mg clopidogrel maintenance dose over 28 days (phase II).&#xD;
&#xD;
      Outcome Measures: Primary outcome measure is the change in BP from baseline. Secondary&#xD;
      outcome measures are changes in biomarkers of platelet and endothelial function and their&#xD;
      correlation with BP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood pressure</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>markers of platelet and endothelial function</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Blood Pressure</condition>
  <condition>Endothelial Function</condition>
  <condition>Platelet Function</condition>
  <arm_group>
    <arm_group_label>Hypertensive individuals: clopidogrel (600 mg, bolus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertensive individuals: clopidogrel (75 mg daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normotensive individuals: clopidogrel (600 mg, bolus)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normotensive individuals: clopidogrel (75 mg, daily)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Hypertensive individuals: clopidogrel (600 mg, bolus)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Hypertensive individuals: clopidogrel (75 mg daily)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Normotensive individuals: clopidogrel (600 mg, bolus)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Normotensive individuals: clopidogrel (75 mg, daily)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with coronary artery disease (CAD) and a clinical presentation of stable&#xD;
             angina pectoris or acute coronary syndrome who had undergone percutaneous coronary&#xD;
             intervention (PCI) with stent implantation&#xD;
&#xD;
          -  5-year history of essential arterial hypertension with a systolic BP between 140 and&#xD;
             170 mmHg or no hypertension (systolic BP &lt;140mg Hg and diastolic BP &lt;90 mmHg)&#xD;
&#xD;
          -  treatment with clopidogrel (75 mg per day) for 6 to 12 months after PCI&#xD;
&#xD;
          -  continuous use of aspirin (100 mg per day)&#xD;
&#xD;
          -  no change in drug therapy within 3 months prestudy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  stent thrombosis or another ischemic cardiovascular event following PCI&#xD;
&#xD;
          -  use of other antiplatelet drugs or anticoagulants within 3 months prestudy&#xD;
&#xD;
          -  surgery within 3 months prestudy&#xD;
&#xD;
          -  arrhythmia&#xD;
&#xD;
          -  valvular heart disease&#xD;
&#xD;
          -  hematologic disorder&#xD;
&#xD;
          -  severe renal disorder&#xD;
&#xD;
          -  severe hepatic disorder&#xD;
&#xD;
          -  chronic inflammatory disorder&#xD;
&#xD;
          -  autoimmune disorder&#xD;
&#xD;
          -  acute or chronic infection&#xD;
&#xD;
          -  active malignancy&#xD;
&#xD;
          -  a body-mass index below 18.5 or above 40 kg/m2&#xD;
&#xD;
          -  nonadherence to therapy&#xD;
&#xD;
          -  nonattendance to control visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>D-50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Antonius Hospital Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML; CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003 Mar 20;348(12):1104-11.</citation>
    <PMID>12646667</PMID>
  </reference>
  <reference>
    <citation>Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M, Tschentscher P, Meinertz T, Böger R, Baldus S. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):1648-52. Epub 2006 May 4.</citation>
    <PMID>16675725</PMID>
  </reference>
  <reference>
    <citation>Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998 Feb 5;391(6667):591-4.</citation>
    <PMID>9468137</PMID>
  </reference>
  <reference>
    <citation>Chen C, Chai H, Wang X, Jiang J, Jamaluddin MS, Liao D, Zhang Y, Wang H, Bharadwaj U, Zhang S, Li M, Lin P, Yao Q. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood. 2008 Oct 15;112(8):3205-16. doi: 10.1182/blood-2008-03-143479. Epub 2008 Jul 24.</citation>
    <PMID>18658029</PMID>
  </reference>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>April 26, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <last_update_submitted>April 27, 2010</last_update_submitted>
  <last_update_submitted_qc>April 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dirk Taubert</name_title>
    <organization>University of Cologne</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

